Gene · 6607
NIH grants1,484
NIH grants whose papers are about the gene, through NIH's grant-paper links.
441 to 460 of 1,484
Download this page as JSON| Grant | Title | SMN2 papers | Newest fiscal year |
|---|---|---|---|
| K99GM147352 | Human centromere variation and function | 1 | 2022 |
| K99HL163805 | In vivo precision genome editing to correct genetic disease | 1 | 2022 |
| K99NS119743 | Precision Base Editing for the Treatment of Motor Neuron Diseases | 1 | 2022 |
| P01CA214274 | Mechanism-Based Targeting of Mantle Cell Lymphoma | 1 | 2022 |
| P01HL066299 | Lung endothelial cell phenotypes | 1 | 2022 |
| P20AG068024 | UAB Alzheimer's Disease Research Center | 1 | 2022 |
| P20AG068053 | Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC) | 1 | 2022 |
| P20AG068077 | New Mexico Alzheimer's Disease Research Center | 1 | 2022 |
| P20GM103639 | Mentoring Translational Cancer Research in Oklahoma | 1 | 2022 |
| P20GM121325 | Personalized Medicine in Nevada COBRE | 1 | 2022 |
| P30GM127200 | Nebraska Center for Nanomedicine | 1 | 2022 |
| R01AG059716 | Genetic Drivers of Resilience to Alzheimer's Disease | 1 | 2022 |
| R01AG060747 | The Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort | 1 | 2022 |
| R01AG061796 | Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in AD | 1 | 2022 |
| R01CA081237 | Mechanism of P73-dependent Tumor Suppression | 1 | 2022 |
| R01CA215072 | Developing miR-10b targeting for glioblastoma | 1 | 2022 |
| R01CA224433 | The feedback loop between ferredoxin reductase and the p53 family in tumor suppression | 1 | 2022 |
| R01GM073850 | Basis of Gene Regulation by Purine and Cobalamine Riboswitches | 1 | 2022 |
| R01GM123312 | The Role of Retroelements in Centromere Function | 1 | 2022 |
| R01GM127585 | Cell Penetration Profiling for Biotherapeutics | 1 | 2022 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/grants?page=23